CHA Vaccine Research Institute Company Description

Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases.

Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in pre-clinical planning stage for the prevention of Herpes Zoster.

The company also develops influenza vaccine, recombinant MBL, TB vaccine, and cancer vaccine, as well as anti-cancer immunotherapy drugs.

Cha Vaccine Research Institute Co., Ltd. was incorporated in 2000 and is headquartered in Seongnam-si, South Korea.